Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | HPGD | P15428 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7537945 | 0.92 | HPGD (0.67) | LMNAHPGDTSHRKMT2ASLC10A6 | |
| SCHEMBL2749317 | 0.89 | LMNA (0.62) | LMNAHPGDTSHRKMT2ASLC10A6 | |
| SCHEMBL1200313 | 0.87 | HPGD (0.80) | LMNAHPGDTSHRKMT2ASLC10A6 | |
| SCHEMBL1199735 | 0.87 | LMNA (1.00) | LMNAHPGDTSHRKMT2ASLC10A6 | |
| SCHEMBL1199098 | 0.86 | LMNA (0.78) | LMNAHPGDTSHRKMT2ASLC10A6 | |
| SCHEMBL2750244 | 0.86 | LMNA (0.78) | LMNAHPGDTSHRKMT2ASLC10A6 | |
| SCHEMBL1199804 | 0.86 | HPGD (0.78) | LMNAHPGDTSHRKMT2ASLC10A6 | |
| SCHEMBL4572271 | 0.86 | TSHR (0.62) | LMNAHPGDTSHRKMT2ASLC10A6 | |
| SCHEMBL532975 | 0.85 | ACLY (0.69) | LMNAHPGDTSHRKMT2AALDH1A1 | |
| SCHEMBL1199332 | 0.85 | LMNA (0.76) | LMNAHPGDTSHRKMT2ASLC10A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2415760-A2 | CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| EP-2207772-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-7579340-B2 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | PFIZER INC (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579340-B2 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | PFIZER INC (US) | 2009-08-25 | — | — | US | disclosed |
| US-7288538-B2 | Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288538-B2 | Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288538-B2 | Cardiovascular homeostasis through combination of direct neuronal control and systemic neurohormonal activation | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | disclosed |
| EP-1610753-A4 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1610753-A2 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-03 | — | — | US | disclosed |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004073634-A2 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2002028353-A2 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | CCR9, CCR1, CCR10 | LMNA 4182/4885HPGD 2182/4885TSHR 518/4885 |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | LMNA 3809/4885HPGD 1517/4885TSHR 1741/4885 |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | LMNA 3809/4885HPGD 1517/4885TSHR 1741/4885 |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | BRDT, TXN, TXNRD2 | LMNA 4540/4885HPGD 166/4885TSHR 911/4885 |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | LMNA 3295/4885HPGD 2415/4885TSHR 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.